Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
The Doctors of USC
A Double-Blind, Placebo-Controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, a Thrombopoietin Receptor Agonist, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who are Not Candidates for Anti-Viral Treatment with Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia.
Non-Cancer Related; Therapeutic
Open to Accrual
Biological Response Modifier
Defintions of terms and FAQ about clinical trials.
Howard Liebman, M.D.
Other Trial Staff:
Laurie Hornor, R.N., Melissa Peralta, D.M.
to see study documents.
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.